Journal of the American Society of Nephrology · 2012 · 69 citations · 36 references
MedicineNephrologyPhysiologyMolecular PharmacologyRenal PathophysiologyRenal PharmacotherapyGlomerular PathophysiologyHypertension ManagementHypertensive NephropathyPodocyte InjuryRenal DiseaseRenal HemodynamicsAntioxidant PropertiesCardioprotective TherapyDietary Salt IntakeMesangial ExpansionProteinuria ReductionRenin-angiotensin System BlockadeRenin-angiotensin-aldosterone System BlockadeRenoprotective Effects
Natriuretic peptides produced by the heart in response to cardiac overload exert cardioprotective and renoprotective effects by eliciting natriuresis, reducing BP, and inhibiting cell proliferation and fibrosis. These peptides also antagonize the renin-angiotensin-aldosterone system, but whether this mechanism contributes to their renoprotective effect is unknown. Here, we examined the kidneys of mice lacking the guanylyl cyclase-A (GC-A) receptor for natriuretic peptides under conditions of high aldosterone and high dietary salt. After 4 weeks of administering aldosterone and a high-salt diet, GC-A knockout mice, but not wild-type mice, exhibited accelerated hypertension with massive proteinuria. Aldosterone-infused GC-A knockout mice had marked mesangial expansion, segmental sclerosis, severe podocyte injury, and increased oxidative stress. Reducing the BP with hydralazine failed to lessen such changes; in contrast, blockade of the renin-angiotensin-aldosterone system markedly reduced albuminuria, ameliorated podocyte injury, and reduced oxidative stress. Furthermore, treatment with the antioxidant tempol significantly reduced albuminuria and abrogated the histologic changes. In cultured podocytes, natriuretic peptides inhibited aldosterone-induced mitogen-activated protein kinase phosphorylation. Taken together, these results suggest that renoprotective properties of the endogenous natriuretic peptide/GC-A system may result from the local inhibition of the renin-angiotensin-aldosterone system and oxidative stress in podocytes.
36
Masashi Mukoyama, Kazuwa Nakao, Kiminori Hosoda et al. · Journal of Clinical Investigation · 1991 · 1.4K citations · Full text
Bardoxolone Methyl and Kidney Function in CKD with Type 2 Diabetes
Pablo E. Pérgola, Philip Raskin, Robert D. Toto et al. · New England Journal of Medicine · 2011 · 876 citations · Full text
Medicine, Endocrinology, Nephrology +16